HHS - Report: 650% Spike In Cannabis Medicine Trials Prioritizing Chronic And Neuropathic Pain | Benzinga
Could the future of healthcare be intertwined with cannabis-based medicines?
A recent report by Prohibition Partners, a data, media and tech company operating in the cannabis industry, reveals a remarkable 650% surge in clinical trials using cannabis-based medicines to alleviate symptoms associated with conditions such as cancer, epilepsy and autism spectrum disorder since 2010.
Stephen Murphy, CEO of Prohibition Partners, noted that this recommendation could bridge the gap between medical and adult-use cannabis, further advancing patient access and pharmaceutical industry involvement in meeting patient demand.
Biden Administration's Cannabis Recommendation: Implications for Access and Industry
The report highlights the potential for cannabinoid-based treatments in various medical fields. The findings come as the Department of Health and Human Services (HHS) recommended reclassifying ...